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Background: Citrate, the currently preferred anticoagulant for continuous veno-venous hemofiltration (CVVH), may
influence acid-base equilibrium.
Methods: The effect of 2 different citrate solutions on acid-base status was assessed according to the Stewart-
Figge approach in two consecutive cohorts of critically ill adult patients. The first group received Prismocitrate 10/2
(PC10/2; 10 mmol citrate/L). The next group was treated with Prismocitrate 18/0 (PC18; 18 mmol citrate/L). Both
groups received bicarbonate-buffered fluids in post-dilution.
Results: At similar citrate flow, the metabolic acidosis present at baseline in both groups was significantly attenuated
in PC18 patients but persisted in PC10/2 patients after 24 h of treatment (median pH 7,42 vs 7,28; p = 0.0001). Acidosis
in the PC10/2 group was associated with a decreased strong ion difference and an increased strong ion gap
(respectively 43 vs. 51 mmol/L and 17 vs. 12 mmol/L, PC10/2 vs. PC18; both p = 0.001). Chloride flow was higher
in PC10/2 than in PC18 subjects (25.9 vs 14.3 mmol/L blood; p < 0.05).
Conclusion: Correction of acidosis was blunted in patients who received 10 mmol citrate/L as regional anticoagulation
during CVVH. This could be explained by differences in chloride flow between the applied citrate solutions inducing
hyperchloremic acidosis.
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Continuous veno-venous hemofiltration (CVVH) under
regional citrate anticoagulation (RCA) is increasingly
used for treatment of acute kidney injury (AKI) in critic-
ally ill patients [1]. As a calcium-chelating agent, citrate
effectively blocks coagulation activation in the extracor-
poreal circuit which enhances filter lifespan at low risk of
bleeding [2]. However, citrate may cause adverse meta-
bolic effects. Citrate metabolization produces bicarbonate,
hence generating metabolic alkalosis. Conversely, in pa-
tients with decreased capacity to metabolize citrate (eg
hepatic failure), accumulation can lead to high anion-gap
metabolic acidosis [3–5]. Acid-base status is also affected
by the amount of administered chloride and bicarbonate
buffer, and occasionally by respiratory (over)compensation
[6, 7]. Finally, when administered as a trisodium salt, ex-
cess citrate may induce hypernatremia [8].
Egi et al. were the first to document changes in acid-
base balance in patients undergoing RCA-CVVH [9].
Since then, many attempts were undertaken to find the
optimal citrate solution that allowed swift and effective
control of acidosis whilst avoiding rebound alkalosis dur-
ing continuous renal replacement therapy (CRRT) [10,
11]. Within this context, we studied the metabolic impact
of two different commercially available citrate formulas
(Prismocitrate 10/2 (PC10/2; 10 mmol citrate/L, Gambro-
Hospal) and Prismocitrate 18/0 (PC18; 18 mmol citrate/L,
Gambro-Hospal) in a cohort of critically ill patients with
AKI undergoing RCA-CVVH. We based our metabolic
approach on the Stewart-Figge method [12–15] to assess
whether a difference existed in occurrence of metabolic
acidosis between the two citrate protocols and to deter-
mine which factor(s) affected this metabolic disorder.
Methods
The study was performed in the intensive care unit
(ICU) of the University Hospital Brussels and conductedTable 1 Patient characteristics and causes of AKI
Prismocitr
Number of patients (n) 28
Age (years) (median [range]) 73 (65–82
Male gender (n, %) 17/28 (61
Underlying disease/condition & cause of AKI (n, %)
Sepsis 9/28 (32 %
Post cardiac surgery 5/28 (18 %
Post general surgery 7/28 (25 %
Other 7/25 (25 %
APACHE II score (median [range]) 32 (23–41
Mechanical ventilation (days) (median [range]) 11 (1–24)
Vasopressor requirement (n, %) 86 %
Abbreviations: APACHE II acute physiology and chronic health evaluation score II, LOin compliance with the Helsinki Declaration. The Cen-
tral Ethical Committee of the University Hospital ap-
proved the study protocol (BUN 143201318818). Due to
its retrospective and observational before-after design,
the need for informed consent was waived.
Patients were eligible when presenting AKI requiring
RCA-CVVH treatment. Inclusion criteria were: age ≥
18 years, presence of at least an AKI “RIFLE injury”
score [16], and no contra-indication for RCA. Exclusion
criteria were: patients already treated with CVVH during
their ICU stay or receiving CVVH at time of enrolment,
a high likelihood of dying within the first 24 h, impossi-
bility to provide a correct vascular access, and Child-
Pugh grade C liver cirrhosis. Baseline characteristics,
including causes of AKI and incidence of shock are
given in Table 1.
Patients were not randomized to receive either PC10/2
or PC18 but consecutively included within one treat-
ment group. In fact, RCA with PC10/2 was initially ap-
plied in all patients on CVVH. At a given moment, we
decided to replace PC10/2 by PC18. The reasons for
changing the concentration of citrate were the follow-
ings: initially, all patients requiring CVVH in our ICU
received PC10/2 for regional anticoagulation. To obtain
better metabolic control (and especially better control of
metabolic acidosis), we decided to replace PC10/2
(10 mmol citrate/L) by PC18 (18 mmol citrate/L). For
practical reasons (storage capacity, short shelf-life of the
citrate liquids, potential prescription errors), the hospital
pharmacy did not make the two citrate solutions simul-
taneously available but delivered the PC18 solution after
the PC10/2 stock was entirely consumed. Thus, a first
group of patients received PC10/2 and, subsequently, a
second group of patients was started on PC18. Regard-
ing citrate dosage used during the study, these two dos-
age regimens (PC 18 & PC 10/2) fall within accepted
dosing range for citrate anticoagulation. Solutions wereate 10/2 Prismocitrate 18 P value
31
) 68 (55–82) 0.298
%) 21/31 (68 %) 0.598
) 9/31 (29 %) 0.98
) 10/31(32 %) 0.33
) 4/31(13 %) 0.39
) 8/31(26 %) 0.90
) 27 (20–34) 0.109
14.6 (2–26) 0.167
77 % 0.451
S length of stay, AKI acute kidney injury
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Gambro-Baxter. In- and exclusion criteria were identical
for both study periods. CVVH was performed with the
Prismaflex device (Gambro, Lund, Sweden) using an
acrylonitrile 69 surface treated (AN69 ST) 150 mem-
brane. Veno-venous access was obtained via a 13 F
double-lumen polyurethane catheter (Joline, Swiss Con-
federation) inserted in the right internal jugular or a
femoral vein. CVVH was delivered according to a dedi-
cated protocol inspired by Tolwani et al. [17] and
presented in detail previously [6]. This included stan-
dardized order sets and initial settings for all patients.
Blood flow rate was set at 150 mL/min. Calcium chlor-
ide initially ran at 6 mL/h through a separate central
venous line. Calcium infusion was titrated to maintain
plasma ionized calcium levels between 1,0 and 1,2 mmol/
L [6]. PC10/2 was delivered before the filter and started at
a rate of 2200 mL/h. A bicarbonate-buffered solution
(Prismasol 2) was infused in post-dilution, starting at
800 mL/h. In the PC18 group, citrate was delivered at a
starting rate of 1500 mL/h and another bicarbonate buffer
(Prismocal B22) in post-dilution at 400 mL/h. Detailed
characteristics of the citrate and substitution fluids are
shown in Table 2. Arterial blood gases, lactate, and serum
electrolytes, including systemic and post-filter ionized cal-
cium, were analyzed every 4 h. Acid-base status was evalu-
ated with the Stewart-Figge method. This approach
postulates that acid-base balance and pH depend on the
difference between concentrations of strong cations and
strong anions (ie the strong ion difference; SID), the
PaCO2, and the total concentration of weak acids. It intro-
duces the term “apparent strong ion difference” (SIDa)
calculated as: ([Na+] + [K+] + [Mg2+] + [Ca2+]) - ([Cl−] -
[lactate−]) (concentrations in mmol/L). The normal range
for SIDa is approximately 40–44 mmol/L [18]. Since this
equation does not account for weak acids (albumin, phos-
phate and CO2), the effective strong ion difference (SIDe)Table 2 Composition of citrate and bicarbonate-buffered solutions












Values for citrate, citric acid,electrolytes, lactate and SIDa are expressed in mmol/Lwas calculated as (1000 × 2.46 × 10−11 × pCO2 / 10
-pH)
+ [albumin] × (0.12 × pH - 0.631) + [phosphate] × (0.309 ×
pH - 0.469) (with pCO2 in mmHg, albumin in g/L and
phosphate in mmol/L) [17]. The SIDa to SIDe difference
should equal zero unless unmeasured charges are present
in the blood. These charges are captured by the strong ion
gap (SIG = SIDa - SIDe). A positive SIG value represents
unmeasured anions that are needed to account for the
measured pH, measured levels of strong ion and weak
acids, and to assure iso-electricity [18]. Statistical analysis
was performed using SPSS version 20 for Windows (SPSS
Inc., Chicago, IL, USA). Chi-square and Fisher exact test
were used to compare categorical variables between
groups. The Mann-Whitney U test was applied for com-
parison of non-normally distributed parameters and the
Wilcoxon test was used for comparing variables within a
group. Values were expressed as medians (range) unless
indicated otherwise.
Results
Twenty-eight patients were enrolled in the PC10/2
group and 31 patients in the PC18 group. Treatment
groups did not significantly differ for age, gender, type of
disease, disease severity, presence of shock, and duration
of mechanical ventilation. The evolution of relevant
acid-base variables and electrolyte levels during the
study are displayed in Table 3. Pre-treatment pH and
chloride levels were comparable between groups ([7.26
(7.12–7.40) vs. 7.33 (7.22–7.44); p = 0.095] and [105 (99–
112) vs. 106 (99–113) mmol/L; p = 0.326], PC10/2 vs.
PC18). After 24 h of treatment, pH remained low in the
PC10/2 group whereas it normalized in the PC18 group
[7.28 (7.22–7.34) vs. 7.42 (7.37–7.47); p = 0.0001]. PC10/
2 patients had higher baseline lactate concentrations.
Thereafter, lactate equally decreased in both groups
[from 4.6 (0–10.3) to 3.1 (0.2 – 6); p > 0.05 in PC10/2
patients and from 2.5 (0–5) to 2.1 (0.3–3.9); p > 0.05 inincluding their calculated SIDa











Table 3 Relevant acid base variables and electrolytes at baseline
(T0) and after 24 h (T24)
Variables Prismocitrate 10/2 Prismocitrate 18 P value
pH T0 7,26 (7,12 – 7,40) 7,33 (7,22 – 7,44) 0.095
pH T24 7,28 (7,22 – 7,34) 7,42 (7,37 – 7,47) 0.0001
Na + T0 138 (133–144) 142 (134–149) 0.042
Na + T24 136 (133–139) 139 (135–145) 0.006
K+ T0 4,5 (3,7 – 5,3) 4,4 (3,7 – 5,3) 0.873
K+ T24 3,8 (3,4 – 4,2) 3,8 (3,4 – 4,2) 0.632
Cl- T0 105 (99–112) 106 (99–113) 0.326
Cl- T24 105 (102–108) 100 (95–105) 0.0001
Ca2+ T0 7,3 (6,4 – 7,2) 7,4 (6,6 – 8,2) 0.611
Ca2+ T24 8,6 (7,9 – 9,3) 9,2 (8,3 – 10,1) 0.004
Mg2+ T0 2 (1,6 – 2,4) 2,3 (1,8 – 2,8) 0.01
Mg2+ T24 1,8 (1,4 – 2,2) 2 (1,7 – 2,3) 0.040
SIDa T0 43 (38–48) 47 (41–53) 0.003
SIDe T0 27 (18–36) 39 (31–47) 0.0001
SIG T0 17 (11–23) 10 (6–16) 0.0001
SIDa T24 43 (40–43) 51 (47–55) 0.0001
SIDe T24 24 (19–29) 39 (35–43) 0.0001
SIG T24 17 (13–21) 12 (8–16) 0.0001
Lactate T0 4,6 (0–10,3) 2,5 (0–5) 0,031
Lactate T24 3,1 (0,2 – 6) 2,1 (0,3–3,9) 0,140
Values for electrolytes, SIDa, SIDe, SIG, and lactate are expressed as medians
(range) in mmol/L
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anymore significantly different at 24 h.
Calculated SIDa values between groups were signifi-
cantly different at baseline [43 (38–48) vs. 47 (41–53)
mmol/L; p = 0.003]. After 24 h, SIDa had increased in
PC18 patients [from 47 (41–53) to 51 (47–55) mmol/L;
p = 0.001] but remained unchanged in the PC10/2 group
[from 43 (38–48) to 43 (40–43); p > 0.05], resulting in a
significantly higher SIDa in PC18 as compared with
PC10/2 subjects (43 vs. 51 mmol/L; p = 0.001). At initi-
ation of therapy, sodium concentration was lower in the
PC10/2 than in the PC18 group [138 (133–144) vs. 142
(134–149) mmol/L; p = 0.04]. After 24 h, sodium con-
centration decreased in both groups, remaining signifi-
cantly lower in the PC10/2 group as compared with the
PC18 group [136 (133–139) vs. 139 (135–145) mmol/L;
p = 0.006]. Calculated citrate flow was not statistically
different between the two treatment periods (2.9 vs.
3 mmol/L of blood accessing the filter; p > 0.05). How-
ever, when differences in chloride concentration (106 vs.
86 mmol/L) and chloride flow (9.9 vs 5.4 mmol/L of
blood accessing the filter) between the two citrate for-
mulations were related to variations in citrate volume
given between the two periods (2200 vs.1500 mL/h), the
chloride flow per liter blood accessing the filter wasfound to be significantly higher in the PC10/2 group
(25.9 vs. 14.3 mmol/L blood; PC10/2 vs. PC18; p < 0.05).
This accounted for the difference in chloride levels be-
tween groups after 24 h of treatment [105 (102–108)
vs.100 (95–105) mmol/L, PC10/2 vs. PC18; p = 0.0001].
SIG at 24 h also remained higher in the PC10/2 group
(17 vs.12 mmol/L, PC10/2 vs. PC18; p = 0.001). At the
end of study, none of the PC10/2 patients reached a pH
>7.5 but 25 % had a SIDa > 45 mmol/L. In the PC18
group, 10.3 % of the patients had pH values > 7.5
whereas 93 % were diagnosed with a SIDa > 45 mmol/L.
Discussion
The buffering capacity of a citrate solution depends on
the conversion of trisodium citrate to citric acid (Na3ci-
trate + 3H2CO3→ citric acid (C6H8O7) + 3NaHCO3) and
thus to the proportion of sodium as a cation. Hence, 1
mmoL trisodium citrate provides the same buffer
strength as 3 mmol sodium bicarbonate, assuming that
citrate is completely metabolized. Citric acid does not
act as a buffer [4, 8, 18]. Following citrate metabolism,
the remaining sodium increases the SIDa. Increasing
SIDa (eg by infusing Plasmalyte®) produces alkalosis
while the administration of a zero-SIDa solution (eg
NaCl 0.9 %) will decrease SIDa and contribute to meta-
bolic acidosis. Our findings suggest that a higher
chloride-containing citrate solution (PC10/2) for RCA-
CVVH may significantly reduce alkalosis-buffering cap-
acity. One would expect that administration of PC10/2
(30 mmol/L of buffer equivalent) should be associated
with a metabolic acidosis. Looking from a pure buffer
equivalence perspective, this acidosis is considered to be
primarily determined by a decrease in SIDa [10, 11]. Ac-
cordingly, PC18 (54 mmoL of buffer equivalent) should
lead to more rapid correction of acidosis and progressive
development of metabolic alkalosis. Before the start of
CVVH, both patient groups had mild metabolic acidosis.
This acidosis resulted from increased unmeasured an-
ions (high SIG) in the presence of an increased lactate
level and was more pronounced in the patients receiving
PC10/2 [19–21]. Within 24 h, acidosis was completely
reversed in all patients who received the solution with a
higher citrate concentration (PC18) along with a de-
crease in serum chloride and an increase in SIDa. In
contrast, patients who received PC10/2, developed hyper-
chloremic acidosis. SIDa and SIG in this group remained
unchanged which counteracted citrate-induced metabolic
alkalosis. Since citrate flow entering the filter was similar
during the two study periods (the difference in citrate con-
centrations being compensated by variations in citrate vol-
ume), the observed largely uncorrected acidosis and
higher SIG at 24 h in the PC10/2 group is most plausibly
explained by the higher chloride content of the PC10/2
solution. The lower bicarbonate concentration in the
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PC10/2 subjects (22 vs. 32 mmol/L) cannot account for
the less rapid correction of acidosis. Rather, this low bicar-
bonate load should have attenuated late rebound alkalosis.
Baseline lactate was higher in the PC10/2 group. However,
lactate levels had decreased in both PC10/2 and PC18 pa-
tients at 24 h. At that time, concentrations were no longer
different between groups making it unlikely that lactate
significantly contributed to the persisting metabolic acid-
osis in patients receiving PC10/2. This leads to hypothesize
that the high chloride-containing citrate solution used for
RCA-CVVH significantly reduces alkalosis-buffering cap-
acity and thus blunts correction of acidosis. This “blunting
effect” may be explained by differences in chloride flow be-
tween the applied citrate solutions inducing hyperchlore-
mic acidosis.
Our findings argue against currently used therapeutic
approaches. To date, clinicians try to correct metabolic
acidosis during CVVH by administering additional bicar-
bonate infusion [17, 22]. However, excess intravenous bi-
carbonate may cause unwarranted side-effects and even
increase mortality [22]. Consequently, new citrate for-
mulations have been implemented to avoid rebound
metabolic alkalosis whilst assuring timely correction of
acidosis and obviating the need to infuse intravenous bi-
carbonate. Our study underscores a potential role of the
“forgotten” chloride anion in acid-base equilibrium [11,
18, 20]. Different citrate formulations, albeit infused at
similar flow rates and sharing equivalent citrate-related
buffer strength, may exhibit divergent capacity and speed
to correct acidosis because of a substantial difference in
chloride content. The lower SIDa and the higher SIG
after 24 h of CVVH in patients treated with PC10/2 as
compared with PC18 were related to a higher plasma
chloride concentration. Interestingly, this untoward
“side-effect” associated with citrate formulations has
been alluded to [22–26] but was never studied in depth.
Tolwani et al. compared a 0.67 % with a 0.5 % trisodium
citrate replacement solution for continuous veno-venous
hemodiafiltration (CVVHDF). The 0.5 % citrate solution
(18 mmol/L citrate) maintained an appropriate acid-base
balance whereas the 0.67 % solution (23 mmol/L citrate)
resulted in a mild but unexplained alkalosis [17]. Citrate
and chloride flow were comparable between groups and
citrate concentration likely similar as both filter lifespan
and post-filter ionized calcium were not different [17].
We suggest that applying the Stewart-Figge principle in-
stead of a strictly pH-directed approach allows to un-
ravel this intriguing metabolic issue. The 0.5 and 0.65 %
citrate solutions used by Tolwani et al. [17] had a SID of
respectively 54 and 69 mmol/L (ie equivalent of bicar-
bonate generation). Knowing that both solutions con-
tained 140 mmol/L sodium, the principle of solution
electro-neutrality requires chloride levels of respectively89 and 74 mmol/L [18]. Thus, notwithstanding the use
of a chloride-rich dialysate (118.5 mmol/L), the signifi-
cantly lower chloride content of the 0.65 % citrate liquid
induced metabolic alkalosis. Our study results, although
obtained under different CRRT conditions, do corrobor-
ate these findings.
Egi et al. found that increasing the citrate dose during
RCA-CVVH significantly attenuated magnitude and dur-
ation of metabolic acidosis [9]. When administering re-
spectively 11 and 14 mmol/L citrate (ie a SIDa of
respectively 33 and 42 mmol/L), they observed an alka-
linizing effect depending on the SIDa of the replacement
fluid and an acidifying effect due to an increase in un-
measured anions [9, 17]. The highly different citrate flow
between groups (1.83 vs. 3.10 mmol/L blood, 22 vs.
28 mmol/h, and 520 vs. 672 mmol/day) might explain
the observed alkalinizing effect [9]. Compared with our
patients, hyperchloremic metabolic acidosis did not
occur as the difference in chloride flow was less pro-
nounced (18 vs.16.5 mmol/L blood) for a chloride con-
tent of 108 vs. 99 mmol /L [9, 11]. Interestingly, the
recent observation that hypochloremic dialysis can cor-
rect metabolic acidosis by reducing unmeasured anions
indirectly adds support to our findings [27].
Some limitations of our study must be recognized. Its
observational and unblinded “before-after” design with-
out randomizing patients towards a specific treatment
may have rendered comparisons between groups less ac-
curate. A possible effect of the different bicarbonate
post-dilution solutions with different SIDs was not inte-
grated in global acid-base evaluation. However, this
probably had marginal importance since, unlike our
findings, it should have improved acidosis in the patients
receiving the lower citrate concentration [11]. As the
PC10/2 formulation was initiated within the context of a
newly implemented citrate protocol, an inherent learn-
ing process might have biased our results. Still, data
were obtained during 24 h of treatment and an appropri-
ate control group was available. It is unclear whether
any back-diffusion of chloride [28] during CVVH oc-
curred. Finally, one might argue that different results
might be obtained with CVVHDF. However, it is doubt-
ful that CVVHDF would have obviated hyperchloremia
as chloride was provided continuously [28, 29]. Apart
from being more labor-intensive and expensive [28, 30],
CVVHDF also provides no superior control of electro-
lyte balance [31] and eventual competition between con-
vection and diffusion at the inner part of the membrane
may blunt diffusion capacity [32].
Conclusions
In conclusion, the Stewart-Figge approach allowed to
elaborate previous experience showing that metabolic
acidosis is attenuated and buffer capacity increased when
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RCA. We postulate that a greater divergence in chloride
flow accounts for the significant difference in severity
and duration of metabolic acidosis observed in patients
undergoing CVVH who receive different citrate solutions
at similar flow rate and with equal buffer capacity. Our
findings, albeit provocative and suggesting a change in at-
titude towards a more optimal metabolic control during
RCA-CVVH, remain hypothetical and definitely need con-
firmation by a large randomized controlled trial.
Bullet Points
1. RCA-CRRT in patients with AKI and metabolic
acidosis should be performed with Prismocitrate 18.
2. Metabolic alkalosis can be corrected by switching to
Prismocitrate 10/2 or even better by infusing natrium
chloride 0.9 % instead of bicarbonate solution as
substitution fluid.
3. The Stewart-Figge method may represent a better
tool to assess changes in acid-base metabolism during
RCA-CRRT.
4. A divergence in chloride but not citrate flow may be
a plausible explanation for the difference in severity
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